Desvenlafaxine Tablet, Extended Release
Product Images NDC 68071-3790

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68071-3790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3790 3)

Packaging label for Desvenlafaxine 50 mg extended-release tablets by NuCare Pharmaceuticals, Inc. The label indicates a bottle count of 30 tablets. The label includes the NDC 68071-3790-3, manufacturing details by Rubicon Research Private Limited in India, and storage instructions to keep at controlled temperature 68-77°F. It also contains warnings about keeping out of reach of children and contact info for reporting side effects to the FDA.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A forest plot chart showing geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of DESVENLAFAXINE in populations with varying degrees of renal and hepatic impairment, as well as by gender and age groups. The x-axis represents change relative to reference from 0.5 to 3.5.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A pharmacokinetic plot showing the geometric mean ratio and 90% confidence interval for Cmax and AUC in the presence of CYP3A4 inhibitor Ketoconazole. The x-axis represents change relative to reference, ranging from 0.50 to 2.0, with data points and confidence intervals indicating values for Cmax and AUC changes.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A forest plot showing geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) when co-administered with Desvenlafaxine at different doses. The chart compares change relative to reference values, indicating no large deviation from 1.0 across interactions.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A line graph comparing the estimated proportion of patients with relapse over time (in days from randomization) between Desvenlafaxine 50 mg and placebo. The horizontal axis represents time to relapse in days, and the vertical axis shows the estimated relapse percentage. The graph features two lines: a blue solid line for Desvenlafaxine 50 mg and a red dashed line for placebo, indicating relapse rates over nearly 200 days.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A line graph comparing the estimated proportion of patients with relapse (%) over time (days from randomization) between Desvenlafaxine and placebo groups. The x-axis represents time to relapse up to 180 days, and the y-axis shows the proportion of patients relapsed up to 50%. Desvenlafaxine is shown with a solid blue line, and placebo with a dashed red line, indicating a lower relapse rate over time for Desvenlafaxine compared to placebo.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure of Desvenlafaxine, showing its molecular composition including a phenol group, a cyclohexanol ring, a dimethylaminoethyl chain, and a hydrate form with two carboxylic acid groups and a water molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.